News

A potential Parkinson’s treatment called cerebral dopamine neurotrophic factor (CDNF) continues to be safe and well tolerated by patients with moderate disease using it for up to one year in a Phase 1/2 trial, and shows a promising potential to ease motor symptoms and slow disease progression, Herantis Pharma,…

Neupro patches placed on the shin caused significantly less skin irritation and itching in people with Parkinson’s’ disease who previously had site reactions when these transdermal patches were applied elsewhere, a new study has found. The patch’s effectiveness as a…

Scientists at two Australia universities are developing a program that will study the effects of exercise on movement and balance in people with Parkinson’s disease. Researchers at James Cook University (JCU) and La Trobe University are seeking ambulatory patients who are able to perform twice-weekly…

In a real-world clinical setting, Neupro Patches (rotigotine) eased the clinical signs and symptoms of Parkinson’s disease, with more than 70% of patients reporting mild improvement or better, including those 80 years and older, a real-world study shows. …

The Parkinson’s Foundation is expanding its virtual programming to support the Parkinson’s disease (PD) community during the global COVID-19 outbreak. As part of its efforts, the organization is moving its signature fundraising walk event — Parkinson’s Moving Day — online, and adding or enhancing other online…

Levodopa improved handwriting and dexterity tasks among people living with Parkinson’s disease, a recent study found. The results, “Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease,” were published in the Journal of Neural Transmission. Neurological examinations of Parkinson’s patients that seek…

Manufacturing will soon begin on a generic version of the Neupro patch, a transdermal delivery system for rotigotine — a dopamine agonist — to treat Parkinson’s symptoms, Vektor Pharma announced in a press release. Testing of its rotigotine patches will first take place at Vektor’s laboratories in Germany, before quickly moving into…

The Michael J. Fox Foundation (MJFF) has awarded more than $8.8 million in wide-ranging grants to scientists aiming to better understand, diagnose, and treat Parkinson’s disease (PD). The 49 grant awards align with the Foundation’s mission to find a cure for this progressive neurodegenerative disease, and…

The number of people with early-stage Parkinson’s disease who reported sleep disturbances increased over the course of a five-year longitudinal study, with insomnia being the most common sleep problem among this patient population. The frequency of other sleep problems such as…

Scientists have discovered new aggregates of alpha synuclein of various shapes that may play a key role in the onset of Parkinson’s disease. These new aggregates, which are larger than those described in previous studies, form in the presence of phospholipids — large fatty molecules that are…